ÂÜÀòÂÒÂ×

Adrian Hobden has a diverse work experience spanning multiple industries and roles. Adrian is currently serving as the Chief Executive Officer of CereSpir Incorporated since October 2015. Prior to this, they held the position of Board Chairman at Cerespir Inc in 2014 and was a Board Member at Zocere Inc starting from January 2014. In 2013, they were a Board Member at The Hope Funds for Cancer Research. Before that, Hobden worked as a Pharmaceutical consultant at Hobden Consulting LLC starting from July 2011. From July 2009 to July 2011, they served as the President and CEO of Myrexis, Inc. Hobden also held the position of President, Myriad Pharmaceuticals at Myriad Genetics from October 1998 to June 2009. Adrian began their career at Glaxo Group Research and served as the Head of Department from 1981 to 1996. During their tenure at Glaxo Wellcome, they held the positions of Director, Global Business Development, and Director, Global Biotechnology Ventures, both from 1996 to 1998.

Adrian Hobden attended the University of Cambridge from 1972 to 1975, where they obtained a Bachelor of Arts degree in Biochemistry. Adrian then pursued further education at the University of Leicester from 1975 to 1978, earning a Ph.D. in Biochemistry.